Pharvaris (NASDAQ:PHVS) Raised to Hold at Wall Street Zen

Pharvaris (NASDAQ:PHVS) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Other research analysts have also issued reports about the stock. Bank of America boosted their price target on shares of Pharvaris from $27.00 to $30.00 and gave the company a “neutral” rating in a research report on Thursday, December 4th. Leerink Partners set a $38.00 price objective on Pharvaris in a research note on Wednesday, December 3rd. Royal Bank Of Canada started coverage on Pharvaris in a research report on Monday, March 9th. They set an “outperform” rating and a $52.00 target price for the company. Guggenheim upped their target price on Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $41.70.

Pharvaris Trading Down 0.1%

Pharvaris stock opened at $27.35 on Friday. Pharvaris has a 1-year low of $11.51 and a 1-year high of $29.80. The firm has a market capitalization of $1.49 billion, a PE ratio of -8.52 and a beta of -2.78. The firm’s 50 day simple moving average is $26.91 and its 200 day simple moving average is $25.24.

Institutional Trading of Pharvaris

A number of hedge funds have recently made changes to their positions in PHVS. Seven Fleet Capital Management LP purchased a new position in Pharvaris in the fourth quarter worth $1,536,000. XTX Topco Ltd raised its position in Pharvaris by 126.1% during the fourth quarter. XTX Topco Ltd now owns 18,568 shares of the company’s stock valued at $515,000 after purchasing an additional 10,355 shares in the last quarter. Ikarian Capital LLC raised its position in Pharvaris by 131.7% during the fourth quarter. Ikarian Capital LLC now owns 486,856 shares of the company’s stock valued at $13,510,000 after purchasing an additional 276,691 shares in the last quarter. Virtus Investment Advisers LLC lifted its stake in Pharvaris by 66.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 11,011 shares of the company’s stock worth $306,000 after purchasing an additional 4,407 shares during the last quarter. Finally, SummitTX Capital L.P. bought a new stake in Pharvaris during the fourth quarter worth about $634,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.